SG11201407803TA - Nmr measurements of glyca - Google Patents

Nmr measurements of glyca

Info

Publication number
SG11201407803TA
SG11201407803TA SG11201407803TA SG11201407803TA SG11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA SG 11201407803T A SG11201407803T A SG 11201407803TA
Authority
SG
Singapore
Prior art keywords
lllll
international
glyca
north carolina
llll
Prior art date
Application number
SG11201407803TA
Inventor
James D Otvos
Irina Y Shalaurova
Dennis W Bennett
Justyna E Wolak-Dinsmore
Original Assignee
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposcience Inc filed Critical Liposcience Inc
Publication of SG11201407803TA publication Critical patent/SG11201407803TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0044—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2576/00—Medical imaging apparatus involving image processing or analysis
    • A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
    • A61B2576/023—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Signal Processing (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Cardiology (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184483 A1 (51) International Patent Classification: G01N24/08 (2006.01) G01N33/49 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043343 30 May 2013 (30.05.2013) English (30) Priority Data: 61/657,315 8 June 2012 (08.06.2012) 61/711,471 9 October 2012 (09.10.2012) 61/739,305 19 December 2012 (19.12.2012) 13/830,199 14 March 2013 (14.03.2013) English US US us us (71) Applicant: LIPOSCIENCE, INC. [US/US]; 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (US). (72) Inventors: OTVOS, James D.; 1117 Wellstone Circle, Apex, North Carolina 27502 (US). SHALAUROVA, Ir- ina Y.; 315 Ambermore Place, Cary, North Carolina 27519 (US). BENNETT, Dennis W.; 4242 North Morris Blvd., Shorewood, Wisconsin 53211 (US). WOLAK- DINSMORE, Justyna E.; 2808 Mebane Ln., Durham, North Carolina 27703 (US). (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: NMR MEASUREMENTS OF GLYCA 00 •t •t 00 [Continued on next page] (57) Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure level of a \"GlycA\" in arbitrary units or in defined units (e.g., |imol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra. WO 2013/184483 A11 lllll llllllll II llllll III lllll lllll lllll lllll III III III lllll lllll lllll llll lllllll llll llll llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201407803TA 2012-06-08 2013-05-30 Nmr measurements of glyca SG11201407803TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261657315P 2012-06-08 2012-06-08
US201261711471P 2012-10-09 2012-10-09
US201261739305P 2012-12-19 2012-12-19
US13/830,199 US9470771B2 (en) 2012-06-08 2013-03-14 NMR measurements of NMR biomarker GlycA
PCT/US2013/043343 WO2013184483A1 (en) 2012-06-08 2013-05-30 Nmr measurements of glyca

Publications (1)

Publication Number Publication Date
SG11201407803TA true SG11201407803TA (en) 2014-12-30

Family

ID=49712504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407803TA SG11201407803TA (en) 2012-06-08 2013-05-30 Nmr measurements of glyca

Country Status (9)

Country Link
US (3) US9470771B2 (en)
EP (2) EP3839544A1 (en)
JP (1) JP6177899B2 (en)
CN (1) CN104508471B (en)
AU (1) AU2013272014B2 (en)
CA (2) CA3146947A1 (en)
HK (1) HK1207156A1 (en)
SG (1) SG11201407803TA (en)
WO (1) WO2013184483A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9076342B2 (en) 2008-02-19 2015-07-07 Architecture Technology Corporation Automated execution and evaluation of network-based training exercises
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) * 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US20140358451A1 (en) * 2013-06-04 2014-12-04 Arizona Board Of Regents On Behalf Of Arizona State University Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum
DK3074775T3 (en) * 2013-11-27 2018-10-01 Inst Dinvestigacio Sanitaria Pere Virgili Method for characterizing lipoproteins
CA2931648C (en) * 2014-01-06 2022-11-29 Liposcience, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
EP3177939A1 (en) * 2014-09-11 2017-06-14 Liposcience, Inc. Cardiovascular risk evaluations using a risk parameter that includes an hdl and inflammatory biomarker interaction parameter
JP6442053B2 (en) 2014-10-31 2018-12-19 華為技術有限公司Ｈｕａｗｅｉ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏ．，Ｌｔｄ． Curve fitting circuit, analog predistorter, and radio frequency signal transmitter
US10083624B2 (en) 2015-07-28 2018-09-25 Architecture Technology Corporation Real-time monitoring of network-based training exercises
US10803766B1 (en) 2015-07-28 2020-10-13 Architecture Technology Corporation Modular training of network-based training exercises
EP3258285B1 (en) 2016-06-14 2020-10-21 Bruker BioSpin GmbH Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid
DE102016224691A1 (en) * 2016-12-12 2018-06-14 Numares Ag Method for analyzing an NMR spectrum of a lipoprotein-containing sample
FI20177098A1 (en) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Methods and device arrangements for physical activity thresholds reducing risks of diabetes, cardiovascular diseases, inflammations, dementia and mortality in sedentary subjects
WO2019051226A1 (en) 2017-09-07 2019-03-14 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
CN107796946B (en) * 2017-10-20 2019-10-25 中国医学科学院基础医学研究所 The protein marker and application thereof of coronary heart disease in urine
EP3740127A4 (en) * 2018-01-18 2021-07-21 New York University System and method for blood glucose monitoring using magnetic resonance spectroscopy
CN109805898B (en) * 2019-03-22 2024-04-05 中国科学院重庆绿色智能技术研究院 Critical death prediction method based on attention mechanism time sequence convolution network algorithm
US11887505B1 (en) 2019-04-24 2024-01-30 Architecture Technology Corporation System for deploying and monitoring network-based training exercises
WO2024030680A1 (en) 2022-08-05 2024-02-08 Liposcience, Inc. Metabolic vulnerability analyzed by nmr
DE102023110285B3 (en) 2023-04-21 2024-05-08 Universität zu Lübeck, Körperschaft des öffentlichen Rechts NMR MEASUREMENT OF GLYCOPROTEINS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529710A (en) 1981-06-12 1985-07-16 The United States Of America As Represented By The United States Department Of Energy Method of using a nuclear magnetic resonance spectroscopy standard
JPH0698036B2 (en) 1986-10-20 1994-12-07 小野薬品工業株式会社 Selective quantification of amino acids
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
AU2054000A (en) 1999-02-26 2000-09-14 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
CA2367820C (en) 1999-04-22 2009-12-22 James D. Otvos Nmr-method for determining the risk of developing type 2 diabetes
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
WO2003012416A1 (en) 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
CA2487836C (en) 2002-06-14 2014-12-02 Pfizer Inc. Metabolic phenotyping
WO2004040407A2 (en) 2002-10-25 2004-05-13 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
WO2005043171A1 (en) 2003-10-23 2005-05-12 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size
US8013602B2 (en) 2004-04-01 2011-09-06 Liposcience, Inc. NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
WO2006057081A1 (en) 2004-11-24 2006-06-01 Mitsuyo Okazaki Method for analyzing lipoproteins
JP5006524B2 (en) 2005-05-13 2012-08-22 株式会社日立製作所 Signal processing method of NMR apparatus for specifying relaxation time
JP4358814B2 (en) 2005-11-09 2009-11-04 花王株式会社 Sample analysis method
EP2369346B1 (en) 2006-03-24 2014-08-27 Metanomics GmbH Method for diagnosing diabetes type II
WO2007133593A2 (en) 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
WO2008137075A2 (en) 2007-05-02 2008-11-13 President And Fellows Of Harvard College Compositions and methods for the treatment of metabolic disorders and inflammation
US7923257B2 (en) 2007-05-04 2011-04-12 Perkinelmer Health Sciences, Inc. Detecting isomers using differential derivatization mass spectrometry
EP2019311A1 (en) 2007-07-23 2009-01-28 F.Hoffmann-La Roche Ag A method for detecting a target substance by nuclear magnetic resonance
US20110311650A1 (en) 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
CA2741034C (en) 2008-10-20 2021-06-22 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
EP2414535A4 (en) 2009-03-31 2012-12-26 Metabolon Inc Biomarkers related to insulin resistance and methods using the same
US8741788B2 (en) 2009-08-06 2014-06-03 Applied Materials, Inc. Formation of silicon oxide using non-carbon flowable CVD processes
US7935643B2 (en) 2009-08-06 2011-05-03 Applied Materials, Inc. Stress management for tensile films
US8449942B2 (en) 2009-11-12 2013-05-28 Applied Materials, Inc. Methods of curing non-carbon flowable CVD films
US20110136241A1 (en) 2009-12-08 2011-06-09 Stephen Naylor Type ii diabetes molecular bioprofile and method and system of using the same
JP2013517616A (en) 2010-01-06 2013-05-16 アプライド マテリアルズ インコーポレイテッド Flowable dielectrics using oxide liners
JP5823505B2 (en) 2010-05-21 2015-11-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ Method for assessing colorectal cancer and colorectal polyps by measuring urinary metabolites
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
CA2887475C (en) 2012-10-09 2021-12-14 Liposcience, Inc. Nmr quantification of branched chain amino acids

Also Published As

Publication number Publication date
CA3146947A1 (en) 2013-12-12
US11692995B2 (en) 2023-07-04
AU2013272014B2 (en) 2017-05-25
HK1207156A1 (en) 2016-01-22
EP3839544A1 (en) 2021-06-23
WO2013184483A1 (en) 2013-12-12
US10852293B2 (en) 2020-12-01
EP2859339A4 (en) 2016-08-03
EP2859339A1 (en) 2015-04-15
CN104508471A (en) 2015-04-08
US9470771B2 (en) 2016-10-18
US20170003269A1 (en) 2017-01-05
EP2859339B1 (en) 2020-10-28
US20210080452A1 (en) 2021-03-18
JP2015522806A (en) 2015-08-06
AU2013272014A1 (en) 2014-12-18
CN104508471B (en) 2017-09-19
CA2874550A1 (en) 2013-12-12
CA2874550C (en) 2022-04-19
JP6177899B2 (en) 2017-08-09
US20130328561A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
SG11201407803TA (en) Nmr measurements of glyca
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201408793XA (en) Methods related to real-time cancer diagnostics at endoscopy utilizing fiber-optic raman spectroscopy
SG11201407898WA (en) Electrode testing apparatus
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201809294RA (en) Systems and methods for sensor data analysis through machine learning
SG11201408261UA (en) Syringe
SG11201408069XA (en) Hair styling device
SG11201804711RA (en) Compounds and methods for kinase modulation, and indications therefor
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201407610WA (en) Cd33 antibodies and use of same to treat cancer
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201408491SA (en) Analogs of glucagon exhibiting gip receptor activity
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201407662WA (en) Process for the preparation of treprostinil and derivatives thereof
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer